Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × irofulven × Gastrointestinal × Clear all
NCT00003441 2018-10-25

Irofulven in Treating Patients With Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
26 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00003786 2014-03-07

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

University of Chicago

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00003760 2012-08-09

Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
3 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡